APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mild Moderate Primary Hypertension Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Mild Moderate Primary Hypertension Drugs Industry Research Report 2026

29 December 2025115 pages

Choose your research edition.

Industry ResearchMild Moderate Primary Hypertension Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Mild Moderate Primary Hypertension Drugs Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Mild Moderate Primary Hypertension Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mild Moderate Primary Hypertension Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Mild Moderate Primary Hypertension Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Mild Moderate Primary Hypertension Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Mild Moderate Primary Hypertension Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Mild Moderate Primary Hypertension Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Mild Moderate Primary Hypertension Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Mild Moderate Primary Hypertension Drugs include Zhejiang Multinpharma Co., Ltd., SHANDONG QIDU PHARMACEUTICAL CO.,LTD., Novartis, NanJing EASEHEAL Pharmaceutieal Co.,Ltd., Lianhuan Pharma, China Resources Double-Crane Pharmaceutical Co.,Ltd., LIFEON GROUP, Beijing UNION Pharmaceutical FACTORY and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Mild Moderate Primary Hypertension Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Mild Moderate Primary Hypertension Drugs Market by Company

Zhejiang Multinpharma Co., Ltd.

SHANDONG QIDU PHARMACEUTICAL CO.,LTD.

Novartis

NanJing EASEHEAL Pharmaceutieal Co.,Ltd.

Lianhuan Pharma

China Resources Double-Crane Pharmaceutical Co.,Ltd.

LIFEON GROUP

Beijing UNION Pharmaceutical FACTORY

AstraZeneca

Mild Moderate Primary Hypertension Drugs Segment by Type

Mild Essential Hypertension Drugs

Moderate Essential Hypertension Drugs

Mild Moderate Primary Hypertension Drugs Segment by Application

Medical

Others

Mild Moderate Primary Hypertension Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mild Moderate Primary Hypertension Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mild Moderate Primary Hypertension Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mild Moderate Primary Hypertension Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Mild Moderate Primary Hypertension Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Mild Moderate Primary Hypertension Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Mild Moderate Primary Hypertension Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Mild Moderate Primary Hypertension Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Mild Moderate Primary Hypertension Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Mild Moderate Primary Hypertension Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Mild Moderate Primary Hypertension Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Mild Moderate Primary Hypertension Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Mild Moderate Primary Hypertension Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Mild Moderate Primary Hypertension Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Mild Moderate Primary Hypertension Drugs, Product Type & Application Table 14. Global Mild Moderate Primary Hypertension Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Mild Moderate Primary Hypertension Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Zhejiang Multinpharma Co., Ltd. Company Information Table 19. Zhejiang Multinpharma Co., Ltd. Business Overview Table 20. Zhejiang Multinpharma Co., Ltd. Mild Moderate Primary Hypertension Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Zhejiang Multinpharma Co., Ltd. Mild Moderate Primary Hypertension Drugs Product Portfolio Table 22. Zhejiang Multinpharma Co., Ltd. Recent Developments Table 23. SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Company Information Table 24. SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Business Overview Table 25. SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Mild Moderate Primary Hypertension Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Mild Moderate Primary Hypertension Drugs Product Portfolio Table 27. SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis Mild Moderate Primary Hypertension Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Novartis Mild Moderate Primary Hypertension Drugs Product Portfolio Table 32. Novartis Recent Developments Table 33. NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Company Information Table 34. NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Business Overview Table 35. NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Mild Moderate Primary Hypertension Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Mild Moderate Primary Hypertension Drugs Product Portfolio Table 37. NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Recent Developments Table 38. Lianhuan Pharma Company Information Table 39. Lianhuan Pharma Business Overview Table 40. Lianhuan Pharma Mild Moderate Primary Hypertension Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Lianhuan Pharma Mild Moderate Primary Hypertension Drugs Product Portfolio Table 42. Lianhuan Pharma Recent Developments Table 43. China Resources Double-Crane Pharmaceutical Co.,Ltd. Company Information Table 44. China Resources Double-Crane Pharmaceutical Co.,Ltd. Business Overview Table 45. China Resources Double-Crane Pharmaceutical Co.,Ltd. Mild Moderate Primary Hypertension Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. China Resources Double-Crane Pharmaceutical Co.,Ltd. Mild Moderate Primary Hypertension Drugs Product Portfolio Table 47. China Resources Double-Crane Pharmaceutical Co.,Ltd. Recent Developments Table 48. LIFEON GROUP Company Information Table 49. LIFEON GROUP Business Overview Table 50. LIFEON GROUP Mild Moderate Primary Hypertension Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. LIFEON GROUP Mild Moderate Primary Hypertension Drugs Product Portfolio Table 52. LIFEON GROUP Recent Developments Table 53. Beijing UNION Pharmaceutical FACTORY Company Information Table 54. Beijing UNION Pharmaceutical FACTORY Business Overview Table 55. Beijing UNION Pharmaceutical FACTORY Mild Moderate Primary Hypertension Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Beijing UNION Pharmaceutical FACTORY Mild Moderate Primary Hypertension Drugs Product Portfolio Table 57. Beijing UNION Pharmaceutical FACTORY Recent Developments Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca Mild Moderate Primary Hypertension Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. AstraZeneca Mild Moderate Primary Hypertension Drugs Product Portfolio Table 62. AstraZeneca Recent Developments Table 63. Global Mild Moderate Primary Hypertension Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 64. Global Mild Moderate Primary Hypertension Drugs Sales by Region (2021-2026) & (K Units) Table 65. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Region (2021-2026) Table 66. Global Mild Moderate Primary Hypertension Drugs Sales by Region (2027-2032) & (K Units) Table 67. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Region (2027-2032) Table 68. Global Mild Moderate Primary Hypertension Drugs Revenue by Region (2021-2026) & (US$ Million) Table 69. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Region (2021-2026) Table 70. Global Mild Moderate Primary Hypertension Drugs Revenue by Region (2027-2032) & (US$ Million) Table 71. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Region (2027-2032) Table 72. North America Mild Moderate Primary Hypertension Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. North America Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2026) & (K Units) Table 74. North America Mild Moderate Primary Hypertension Drugs Sales by Country (2027-2032) & (K Units) Table 75. North America Mild Moderate Primary Hypertension Drugs Revenue by Country (2021-2026) & (US$ Million) Table 76. North America Mild Moderate Primary Hypertension Drugs Revenue by Country (2027-2032) & (US$ Million) Table 77. Europe Mild Moderate Primary Hypertension Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Europe Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2026) & (K Units) Table 79. Europe Mild Moderate Primary Hypertension Drugs Sales by Country (2027-2032) & (K Units) Table 80. Europe Mild Moderate Primary Hypertension Drugs Revenue by Country (2021-2026) & (US$ Million) Table 81. Europe Mild Moderate Primary Hypertension Drugs Revenue by Country (2027-2032) & (US$ Million) Table 82. Asia Pacific Mild Moderate Primary Hypertension Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Asia Pacific Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2026) & (K Units) Table 84. Asia Pacific Mild Moderate Primary Hypertension Drugs Sales by Country (2027-2032) & (K Units) Table 85. Asia Pacific Mild Moderate Primary Hypertension Drugs Revenue by Country (2021-2026) & (US$ Million) Table 86. Asia Pacific Mild Moderate Primary Hypertension Drugs Revenue by Country (2027-2032) & (US$ Million) Table 87. South America Mild Moderate Primary Hypertension Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. South America Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2026) & (K Units) Table 89. South America Mild Moderate Primary Hypertension Drugs Sales by Country (2027-2032) & (K Units) Table 90. South America Mild Moderate Primary Hypertension Drugs Revenue by Country (2021-2026) & (US$ Million) Table 91. South America Mild Moderate Primary Hypertension Drugs Revenue by Country (2027-2032) & (US$ Million) Table 92. Middle East and Africa Mild Moderate Primary Hypertension Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Middle East and Africa Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2026) & (K Units) Table 94. Middle East and Africa Mild Moderate Primary Hypertension Drugs Sales by Country (2027-2032) & (K Units) Table 95. Middle East and Africa Mild Moderate Primary Hypertension Drugs Revenue by Country (2021-2026) & (US$ Million) Table 96. Middle East and Africa Mild Moderate Primary Hypertension Drugs Revenue by Country (2027-2032) & (US$ Million) Table 97. Global Mild Moderate Primary Hypertension Drugs Sales by Type (2021-2026) & (K Units) Table 98. Global Mild Moderate Primary Hypertension Drugs Sales by Type (2027-2032) & (K Units) Table 99. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Type (2021-2026) Table 100. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Type (2027-2032) Table 101. Global Mild Moderate Primary Hypertension Drugs Revenue by Type (2021-2026) & (US$ Million) Table 102. Global Mild Moderate Primary Hypertension Drugs Revenue by Type (2027-2032) & (US$ Million) Table 103. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Type (2021-2026) Table 104. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Type (2027-2032) Table 105. Global Mild Moderate Primary Hypertension Drugs Price by Type (2021-2026) & (US$/Unit) Table 106. Global Mild Moderate Primary Hypertension Drugs Price by Type (2027-2032) & (US$/Unit) Table 107. Global Mild Moderate Primary Hypertension Drugs Sales by Application (2021-2026) & (K Units) Table 108. Global Mild Moderate Primary Hypertension Drugs Sales by Application (2027-2032) & (K Units) Table 109. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Application (2021-2026) Table 110. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Application (2027-2032) Table 111. Global Mild Moderate Primary Hypertension Drugs Revenue by Application (2021-2026) & (US$ Million) Table 112. Global Mild Moderate Primary Hypertension Drugs Revenue by Application (2027-2032) & (US$ Million) Table 113. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Application (2021-2026) Table 114. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Application (2027-2032) Table 115. Global Mild Moderate Primary Hypertension Drugs Price by Application (2021-2026) & (US$/Unit) Table 116. Global Mild Moderate Primary Hypertension Drugs Price by Application (2027-2032) & (US$/Unit) Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Mild Moderate Primary Hypertension Drugs Distributors List Table 120. Mild Moderate Primary Hypertension Drugs Customers List Table 121. Mild Moderate Primary Hypertension Drugs Industry Trends Table 122. Mild Moderate Primary Hypertension Drugs Industry Drivers Table 123. Mild Moderate Primary Hypertension Drugs Industry Restraints Table 124. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Mild Moderate Primary Hypertension Drugs Product Image Figure 5. Global Mild Moderate Primary Hypertension Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Mild Moderate Primary Hypertension Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Mild Moderate Primary Hypertension Drugs Sales (2021-2032) & (K Units) Figure 8. Global Mild Moderate Primary Hypertension Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Mild Essential Hypertension Drugs Product Image Figure 10. Moderate Essential Hypertension Drugs Product Image Figure 11. Medical Product Image Figure 12. Others Product Image Figure 13. Global Mild Moderate Primary Hypertension Drugs Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of Mild Moderate Primary Hypertension Drugs, Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 Mild Moderate Primary Hypertension Drugs Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Mild Moderate Primary Hypertension Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global Mild Moderate Primary Hypertension Drugs Sales by Region in 2025 Figure 19. Global Mild Moderate Primary Hypertension Drugs Revenue by Region in 2025 Figure 20. North America Mild Moderate Primary Hypertension Drugs Market Size by Country in 2025 Figure 21. North America Mild Moderate Primary Hypertension Drugs Sales Market Share by Country (2021-2032) Figure 22. North America Mild Moderate Primary Hypertension Drugs Revenue Market Share by Country (2021-2032) Figure 23. United States Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Europe Mild Moderate Primary Hypertension Drugs Market Size by Country in 2025 Figure 26. Europe Mild Moderate Primary Hypertension Drugs Sales Market Share by Country (2021-2032) Figure 27. Europe Mild Moderate Primary Hypertension Drugs Revenue Market Share by Country (2021-2032) Figure 28. Germany Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. France Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. U.K. Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Italy Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Netherlands Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Asia Pacific Mild Moderate Primary Hypertension Drugs Market Size by Country in 2025 Figure 34. Asia Pacific Mild Moderate Primary Hypertension Drugs Sales Market Share by Country (2021-2032) Figure 35. Asia Pacific Mild Moderate Primary Hypertension Drugs Revenue Market Share by Country (2021-2032) Figure 36. China Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Japan Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. South Korea Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. India Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Australia Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. China Taiwan Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Southeast Asia Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Southeast Asia Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South America Mild Moderate Primary Hypertension Drugs Market Size by Country in 2025 Figure 45. South America Mild Moderate Primary Hypertension Drugs Sales Market Share by Country (2021-2032) Figure 46. South America Mild Moderate Primary Hypertension Drugs Revenue Market Share by Country (2021-2032) Figure 47. Mexico Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Brazil Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Argentina Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Middle East and Africa Mild Moderate Primary Hypertension Drugs Market Size by Country in 2025 Figure 51. Middle East and Africa Mild Moderate Primary Hypertension Drugs Sales Market Share by Country (2021-2032) Figure 52. Middle East and Africa Mild Moderate Primary Hypertension Drugs Revenue Market Share by Country (2021-2032) Figure 53. Turkey Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Saudi Arabia Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. UAE Mild Moderate Primary Hypertension Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Type (2021-2032) Figure 57. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Type (2021-2032) Figure 58. Global Mild Moderate Primary Hypertension Drugs Price (US$/Unit) by Type (2021-2032) Figure 59. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Application (2021-2032) Figure 60. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Application (2021-2032) Figure 61. Global Mild Moderate Primary Hypertension Drugs Price (US$/Unit) by Application (2021-2032) Figure 62. Mild Moderate Primary Hypertension Drugs Value Chain Figure 63. Mild Moderate Primary Hypertension Drugs Production Mode & Process Figure 64. Direct Comparison with Distribution Share Figure 65. Distributors Profiles Figure 66. Mild Moderate Primary Hypertension Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Mild Essential Hypertension Drugs
  • Moderate Essential Hypertension Drugs
Applications
  • Medical
  • Others
Companies covered
  • Zhejiang Multinpharma Co., Ltd.
  • SHANDONG QIDU PHARMACEUTICAL CO.,LTD.
  • Novartis
  • NanJing EASEHEAL Pharmaceutieal Co.,Ltd.
  • Lianhuan Pharma
  • China Resources Double-Crane Pharmaceutical Co.,Ltd.
  • LIFEON GROUP
  • Beijing UNION Pharmaceutical FACTORY
  • AstraZeneca

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Mild Moderate Primary Hypertension Drugs Market Size (2021-2032)
  4. 2.2.2 Global Mild Moderate Primary Hypertension Drugs Sales (2021-2032)
  5. 2.2.3 Global Mild Moderate Primary Hypertension Drugs Market Average Price (2021-2032)
  6. 2.3 Mild Moderate Primary Hypertension Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Mild Essential Hypertension Drugs
  9. 2.3.3 Moderate Essential Hypertension Drugs
  10. 2.4 Mild Moderate Primary Hypertension Drugs by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Medical
  13. 2.4.3 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Mild Moderate Primary Hypertension Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Mild Moderate Primary Hypertension Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Mild Moderate Primary Hypertension Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Mild Moderate Primary Hypertension Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Mild Moderate Primary Hypertension Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Mild Moderate Primary Hypertension Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Mild Moderate Primary Hypertension Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Mild Moderate Primary Hypertension Drugs, Established Date
  9. 3.9 Global Mild Moderate Primary Hypertension Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Zhejiang Multinpharma Co., Ltd.
  2. 4.1.1 Zhejiang Multinpharma Co., Ltd. Company Information
  3. 4.1.2 Zhejiang Multinpharma Co., Ltd. Business Overview
  4. 4.1.3 Zhejiang Multinpharma Co., Ltd. Mild Moderate Primary Hypertension Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Zhejiang Multinpharma Co., Ltd. Mild Moderate Primary Hypertension Drugs Product Portfolio
  6. 4.1.5 Zhejiang Multinpharma Co., Ltd. Recent Developments
  7. 4.2 SHANDONG QIDU PHARMACEUTICAL CO.,LTD.
  8. 4.2.1 SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Company Information
  9. 4.2.2 SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Business Overview
  10. 4.2.3 SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Mild Moderate Primary Hypertension Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Mild Moderate Primary Hypertension Drugs Product Portfolio
  12. 4.2.5 SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis Mild Moderate Primary Hypertension Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis Mild Moderate Primary Hypertension Drugs Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 NanJing EASEHEAL Pharmaceutieal Co.,Ltd.
  20. 4.4.1 NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Company Information
  21. 4.4.2 NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Business Overview
  22. 4.4.3 NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Mild Moderate Primary Hypertension Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Mild Moderate Primary Hypertension Drugs Product Portfolio
  24. 4.4.5 NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Recent Developments
  25. 4.5 Lianhuan Pharma
  26. 4.5.1 Lianhuan Pharma Company Information
  27. 4.5.2 Lianhuan Pharma Business Overview
  28. 4.5.3 Lianhuan Pharma Mild Moderate Primary Hypertension Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Lianhuan Pharma Mild Moderate Primary Hypertension Drugs Product Portfolio
  30. 4.5.5 Lianhuan Pharma Recent Developments
  31. 4.6 China Resources Double-Crane Pharmaceutical Co.,Ltd.
  32. 4.6.1 China Resources Double-Crane Pharmaceutical Co.,Ltd. Company Information
  33. 4.6.2 China Resources Double-Crane Pharmaceutical Co.,Ltd. Business Overview
  34. 4.6.3 China Resources Double-Crane Pharmaceutical Co.,Ltd. Mild Moderate Primary Hypertension Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 China Resources Double-Crane Pharmaceutical Co.,Ltd. Mild Moderate Primary Hypertension Drugs Product Portfolio
  36. 4.6.5 China Resources Double-Crane Pharmaceutical Co.,Ltd. Recent Developments
  37. 4.7 LIFEON GROUP
  38. 4.7.1 LIFEON GROUP Company Information
  39. 4.7.2 LIFEON GROUP Business Overview
  40. 4.7.3 LIFEON GROUP Mild Moderate Primary Hypertension Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 LIFEON GROUP Mild Moderate Primary Hypertension Drugs Product Portfolio
  42. 4.7.5 LIFEON GROUP Recent Developments
  43. 4.8 Beijing UNION Pharmaceutical FACTORY
  44. 4.8.1 Beijing UNION Pharmaceutical FACTORY Company Information
  45. 4.8.2 Beijing UNION Pharmaceutical FACTORY Business Overview
  46. 4.8.3 Beijing UNION Pharmaceutical FACTORY Mild Moderate Primary Hypertension Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Beijing UNION Pharmaceutical FACTORY Mild Moderate Primary Hypertension Drugs Product Portfolio
  48. 4.8.5 Beijing UNION Pharmaceutical FACTORY Recent Developments
  49. 4.9 AstraZeneca
  50. 4.9.1 AstraZeneca Company Information
  51. 4.9.2 AstraZeneca Business Overview
  52. 4.9.3 AstraZeneca Mild Moderate Primary Hypertension Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 AstraZeneca Mild Moderate Primary Hypertension Drugs Product Portfolio
  54. 4.9.5 AstraZeneca Recent Developments
5 Global Mild Moderate Primary Hypertension Drugs Market Scenario by Region
  1. 5.1 Global Mild Moderate Primary Hypertension Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Mild Moderate Primary Hypertension Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Mild Moderate Primary Hypertension Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Mild Moderate Primary Hypertension Drugs Sales by Region: 2027-2032
  5. 5.3 Global Mild Moderate Primary Hypertension Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Mild Moderate Primary Hypertension Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Mild Moderate Primary Hypertension Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Mild Moderate Primary Hypertension Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Mild Moderate Primary Hypertension Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Mild Moderate Primary Hypertension Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Mild Moderate Primary Hypertension Drugs Market Facts & Figures by Country
  15. 5.5.1 Europe Mild Moderate Primary Hypertension Drugs Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2032)
  17. 5.5.3 Europe Mild Moderate Primary Hypertension Drugs Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Mild Moderate Primary Hypertension Drugs Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Mild Moderate Primary Hypertension Drugs Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Mild Moderate Primary Hypertension Drugs Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Mild Moderate Primary Hypertension Drugs Market Facts & Figures by Country
  35. 5.7.1 South America Mild Moderate Primary Hypertension Drugs Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2032)
  37. 5.7.3 South America Mild Moderate Primary Hypertension Drugs Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Mild Moderate Primary Hypertension Drugs Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Mild Moderate Primary Hypertension Drugs Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Mild Moderate Primary Hypertension Drugs Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Mild Moderate Primary Hypertension Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Mild Moderate Primary Hypertension Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Mild Moderate Primary Hypertension Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Mild Moderate Primary Hypertension Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Mild Moderate Primary Hypertension Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Mild Moderate Primary Hypertension Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Mild Moderate Primary Hypertension Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Mild Moderate Primary Hypertension Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Mild Moderate Primary Hypertension Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Mild Moderate Primary Hypertension Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Mild Moderate Primary Hypertension Drugs Value Chain Analysis
  2. 8.1.1 Mild Moderate Primary Hypertension Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Mild Moderate Primary Hypertension Drugs Production Mode & Process
  5. 8.2 Mild Moderate Primary Hypertension Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Mild Moderate Primary Hypertension Drugs Distributors
  8. 8.2.3 Mild Moderate Primary Hypertension Drugs Customers
9 Global Mild Moderate Primary Hypertension Drugs Analyzing Market Dynamics
  1. 9.1 Mild Moderate Primary Hypertension Drugs Industry Trends
  2. 9.2 Mild Moderate Primary Hypertension Drugs Industry Drivers
  3. 9.3 Mild Moderate Primary Hypertension Drugs Industry Opportunities and Challenges
  4. 9.4 Mild Moderate Primary Hypertension Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst